Digital Health M&A Hits Multi-Year High as Scale Trumps Standalone Growth

Digital health consolidation is running ahead of last year's record, and the numbers leave little room for debate.

The Corum Group counted 149 health tech M&A deals in the first quarter of 2026 alone, a pace that puts the sector on track to top 2025's full-year total of 555. Disclosed deal value hit $22.7 billion in that single quarter, already closing in on last year's $30.3 billion for the entire year. Private equity firms accounted for 31% of Q1 deals, evidence that financial sponsors are not sitting on the sidelines waiting for cheaper entry points.

Capstone Partners tells a similar story in healthcare IT specifically. Through September, deal volume grew 23% year-over-year to 179 transactions, on pace to exceed the record 348 deals logged in full-year 2025. David DeSimone, the firm's managing partner of technology, media and telecom, attributes the momentum to improving buyer confidence, a fuller seller pipeline, and demand for AI-enabled business-to-business assets.

Rock Health's data adds another data point worth flagging. The first half of 2026 produced 115 digital health acquisitions, already ahead of 2025's full-year pace of 199 and well above 2024's 121. Seventy-one of those deals landed in the second quarter, making it the busiest M&A quarter since Q3 2021. Galen Growth found that M&A captured 97.6% of digital health exits in H1 2026, with 84 total exits. Whichever dataset you prefer, the direction is the same.

Why the Deals Are Happening

Three forces are converging here, and none of them are new, but their combined effect is producing an unusually dense M&A cycle.

The first is straightforward platform building. Neil Patel, head of ventures at Redesign Health, describes acquisitions as a tool for expanding into adjacent markets and broadening product suites. Sword Health's $285 million purchase of Kaia Health in January extended its global footprint. Hinge Health's $105 million acquisition of Cylinder Health, closed this month, pushed the musculoskeletal care platform into gastrointestinal care. Patel calls the pattern "a sign of a healthy market," noting that recent funding rounds are effectively war chests for opportunistic M&A. Abridge, which raised $300 million in a Series E in June 2025, later confirmed to Business Insider it was hunting for acquisitions and followed through two months ago with a purchase of Altrina to strengthen agentic AI for clinical workflows.

The second force is talent acquisition disguised as corporate strategy. OpenAI's purchase of Torch in January, aimed at building the data foundation for ChatGPT Health, and Hippocratic AI's acquisition of Grove AI both fit this pattern of buying teams as much as products.

The third and arguably most consequential force is a shift in capital allocation. Eric Bormel, managing director in healthcare at Solomon Partners, points out that venture funding has moved from tech-enabled services toward AI-native solutions, leaving companies from the 2010s and early 2020s vintages to find their own route to profitability. Strategic consolidation is one of the few paths available to that cohort. "We are observing many flavors of digital health companies across tech-enabled services that are actively considering how to leverage scale to drive efficiencies to drive profitable growth," Bormel told Fierce Healthcare.

Revenue cycle management illustrates the trend cleanly. IKS Health bought TruBridge to extend RCM capabilities into rural markets. Med-Metrix acquired Vitalware from Health Catalyst and separately purchased CanAide for automation and Medicaid eligibility work. Innovaccer picked up CaduceusHealth to pair its AI platform with revenue cycle staff serving ambulatory providers. Carlyle took majority stakes in Knack RCM and EqualizeRCM in May. R1 acquired prior-authorization automation company Humata Health. And Thoreau Group, the private equity platform led by Matt Holt, signed a $12 billion agreement to take control of Ensemble Health, arguably the marquee transaction of the cycle so far.

Employer-facing benefits platforms are consolidating for a related but distinct reason: pricing leverage. Patel frames it as simultaneously offensive and defensive. "You want to cover as much surface area as you possibly can for your buyers," he said. Bundled offerings let acquirers win procurement decisions on price rather than best-of-breed comparisons, which rewards whoever can move fastest, whether through faster product development or through acquisition.

Mental health has become its own subsector of dealmaking. Universal Health Services closed an $835 million acquisition of Talkspace, and Spring Health is set to acquire Alma to build what it calls a lifelong mental health platform. Sword Health is separately pursuing Headspace in an all-cash deal reportedly valued between $200 million and $300 million, a transaction that would move the AI-first care company into digital mental health entirely.

What Investors Should Watch

Valuation discipline is the underappreciated part of this story. Bormel notes that outside a small group of high-profile AI companies still commanding outsized multiples, pricing across digital health has normalized to levels that strategic buyers, private equity firms, and public market investors view as sustainable. That is a meaningful departure from the 2021 peak, when Google paid $2.1 billion for Fitbit and Amazon paid $3.9 billion for One Medical amid a broader frenzy of big tech health bets.

The buyer pool has also widened beyond traditional healthcare acquirers. Samsung Electronics bought Xealth a year ago to extend into healthcare, and private equity firms are willing to pay premiums for genuinely profitable, growing assets, as seen in Frazier Healthcare Partners' $490 million purchase of MatrixCare from ResMed and New Mountain Capital's roll-up of Access Healthcare, Thoughtful.ai and SmarterDx into the $1.49 billion Smarter Technologies platform.

For investors tracking this space, the signal to watch is not deal count alone but disclosed value relative to prior years, and whether private equity's 31% share of deals holds or expands as rates stay within a range sponsors find workable. Bormel expects private equity interest to persist into 2027 "so long as rates remain within reason for those investors." Patel, meanwhile, flags medical front-office AI agents as the next likely arena for commoditization-driven consolidation, following the familiar market cycle pattern where intensifying competition among similar technologies precedes a wave of buyouts. Both perspectives point to the same conclusion: this is not a one-year phenomenon but a structural repricing of how digital health companies reach scale.